lu ag06988

Lu AG06988 is a major active metabolite of Lu AG06466, both of which are potent and selective inhibitors of **monoacylglycerol lipase (MAGL)**, the primary enzyme responsible for the degradation of the endocannabinoid ligand 2-arachidonoylglycerol (2-AG)[1][3][4][5]. By inhibiting MAGL, Lu AG06988 is implicated in **modulation of the endocannabinoid system (ECS)**, which plays a role in neuropsychiatric and neurological disorders. Lu AG06988 displays comparable in vitro and in vivo pharmacodynamic profiles to Lu AG06466 and may contribute significantly to MAGL inhibitory effects in clinical studies[1]. The molecule exhibits substantial central nervous system exposure and has been included in phase 1 pharmacodynamic and pharmacokinetic studies as the principal active metabolite of Lu AG06466.